BullFrog AI has signed a commercial agreement with a top 5 global pharmaceutical company to use its bfLEAP® AI platform to identify and prioritize drug targets for major depressive disorder (MDD). This collaboration aims to speed up the customer's drug discovery and clinical development efforts in the MDD market, which was valued at over $8 billion in 2025 and is expected to grow to more than $11 billion by 2032. The deal also grants exclusive access to a target candidate, showcasing BullFrog AI's advanced capabilities in analyzing complex biomedical data. This partnership is seen as a strong validation of BullFrog AI's technology and may expand to other research areas with the customer.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The stock market saw significant gains driven by corporate announcements and high trading volumes, particularly in battery technology, electric vehicles, and green energy sectors. Electrovaya surged 49.05% after announcing a commercial deal with Amaz...
An Akamai Technologies executive sold 3,100 shares as the company shifts focus from its declining content delivery network business to high-growth cloud infrastructure and cybersecurity services. This strategic pivot is supported by a $1.8 billion, s...
Taiwan Semiconductor Manufacturing Company (TSMC) is set to report earnings on July 16, 2026, with analysts expecting revenue around $39.85 billion, up significantly from last year due to high demand for AI chips. Earnings per share are forecasted at...
